|Bid||0.00 x 1200|
|Ask||0.00 x 1300|
|Day's Range||5.77 - 6.33|
|52 Week Range||5.12 - 10.39|
|PE Ratio (TTM)||778.75|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
TORONTO, May 18, 2018 /CNW/ - Cronos Group Inc. (NASDAQ, TSX-V: CRON) ("Cronos Group" or the "Company"), a geographically diversified and vertically integrated cannabis group, announced today it has appointed Jim Rudyk as lead director and has entered into an engagement agreement to retain Athena Advisors LLC ("Athena Advisors") as its agency of record for investor relations and corporate communications. "Since joining the board, Jim has been an integral part of our success and we are excited for his continued leadership and contribution," said Mike Gorenstein, CEO of Cronos Group. Athena Advisors is based in New York City and was founded by Anna Shlimak who spent more than 6 years at the New York Stock Exchange, where she was responsible for communication and relationship development with investors and sell side analysts.
Cronos Group (CRON) reported its first-quarter earnings on May 15 with sales growth of almost 4.8x. Following the earnings release, the stock fell 5% on May 15 and fell another 3.4% on May 16 to 7.7 Canadian dollars. The company cut its recommendation to “sell” from “hold” but raised the price target to 6.5 Canadian dollars from 6 Canadian dollars.
On May 14, Aurora Cannabis (ACB) (ACBFF) announced that it agreed to acquire all of MedReleaf’s (MEDFF) outstanding common shares for about 3.2 billion Canadian dollars in one of the biggest deals in the cannabis sector (MJ). Following the news, MedReleaf stock was heavily traded with a volume of 3.3 million shares and closed at 25.3 Canadian dollars. Read MedReleaf Stock Rises on Aurora Cannabis Acquisition to learn more. Similar to Canopy Growth (WEED), the mean ratings for Aurora Cannabis also improved from 2.3 a month ago in April, which indicates that analysts were more bullish on the stock month-over-month.
Cronos Group (CRON) reported its first-quarter earnings on May 15. The company’s sales rose almost 4.8 times year-over-year to 2.9 million Canadian dollars from 0.5 million Canadian dollars in the first quarter of 2017. Sequentially, sales grew 83% from 1.3 million Canadian dollars.
TORONTO, May 15, 2018 /CNW/ - Cronos Group Inc. (NASDAQ, TSX-V: CRON) ("Cronos Group" or the "Company") today announced financial results for the first quarter ended March 31, 2018. "We are pleased that the strategic initiatives launched in 2017 are coming to fruition," said Mike Gorenstein, CEO of Cronos Group.
NEW YORK, NY / ACCESSWIRE / May 15, 2018 / Cronos Group Inc (NASDAQ: CRON ) will be discussing their earnings results in their Q1 Earnings Call to be held on May 15, 2018 at 8:00 AM Eastern Time. To listen ...
Today, Canopy Growth (WEED) stock surged more than 7% on news of its application to list its common shares on the NYSE (New York Stock Exchange). This news comes on the heels of Aurora Cannabis (ACB)(ACBFF) announcing its acquisition of MedReleaf (MEDFF) today. Read more in MedReleaf Stock Rises on Aurora Cannabis Acquisition.
In the previous part of this series, we discussed how Canadian cannabis stocks’ (HMMJ) forward EV-to-EBITDA (enterprise value-to-earnings before interest, tax, depreciation, and amortization) multiple moved last week. In this part, we’ll compare how these producers’ multiples compare with each other.
In the previous part of this series, we discussed how the median forward EV-to-sales (enterprise value-to-sales) multiple of Canadian cannabis stocks (HMLSF) moved last week. In this part, we’ll look at how these producers’ multiples compare with each other.
Strong sentiment in the cannabis sector pushed ETFs and stocks into positive territory last week. The Horizons Marijuana Life Sciences ETF (HMMJ) closed 4.4% higher, while its US-listed counterpart, the Horizons Marijuana Life Sciences Index ETF (HMLSF), rose 4.8%. Similarly, the Emerging Marijuana Growers Index ETF (HMJR) rose 4.3%, and the Evolve Marijuana ETD (SEED) rose 2.5% between its close on May 4 and its close on May 11.
TORONTO , May 9, 2018 /CNW/ - Cronos Group Inc. (NASDAQ, TSX-V: CRON) ( "Cronos Group" or the "Company" ) will release its financial results for the first quarter ended March 31, 2018 ...
Last week (ended April 27), cannabis-sector ETFs ended in negative territory. The Horizons Marijuana Life Sciences ETF (HMMJ) fell ~4.1%, the Horizons Emerging Marijuana Growers Index ETF (HMJR) fell ~3.8%, and the ETFMG Alternative Harvest ETF (MJ) fell ~4.4%.
New marijuana IPO Cronos Group jumped in early trading after revealing Q4 sales rose 274% to $1.6 million and full-year sales rocketed 636% to $4.1 million.
In the previous part of this series, we compared the forward EV-to-sales multiples of individual cannabis licensed producers (HMMJ) with the peers’ median on April 26. We’ll do a similar comparison for the EV-to-EBITDA1 multiple as well.
TORONTO, April 30, 2018 /CNW/ - Cronos Group Inc. (NASDAQ, TSX-V: CRON) ("Cronos Group" or the "Company") today announced financial results for the fourth quarter and fiscal year ended December 31, 2017. The Company completed significant improvements to the three pre-existing indoor production facilities at Peace Naturals Project Inc. ("Peace Naturals"), to increase production capacity and efficiency.
CEOs of Canadian marijuana growers look like they're trying to defy the laws of supply and demand -- at least at first glance.
Recreational cannabis is just a few months away from being legalized in Canada, and producers (HMMJ) are running at full bore to capture a piece of the market. Let’s revisit the valuation multiples of the most active cannabis players. Looking at the median of only Canadian cannabis producers—including Canopy Growth (WEED), Aurora Cannabis (ACB), MedReleaf (MEDFF), Cronos (CRON), and others mentioned in the chart—we see a similar trend.
TORONTO , April 27, 2018 /CNW/ – Cronos Group Inc. (NASDAQ, TSX-V: CRON) ( "Cronos Group" or the "Company" ) will release its financial results for the fourth quarter and fiscal year ...
On April 20, the cannabis sector saw more positive news came from the US, as Senator Chuck Schumer discussed intentions to introduce legislation decriminalizing cannabis, which currently is a Schedule 1 drug in the US.